skip to main content
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect

Urien, Saik ; Doz, François ; Giraud, Carole ; Rey, Elisabeth ; Gentet, Jean-Claude ; Chastagner, Pascal ; Vassal, Gilles ; Corradini, Nadège ; Auvrignon, Anne ; Leblond, Pierre ; Rubie, Hervé ; Treluyer, Jean-Marc Peer, Hal (Editor)

Cancer chemotherapy and pharmacology, 20 May 2010, Vol.67(3), pp.597-603 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect
  • Autor: Urien, Saik ; Doz, François ; Giraud, Carole ; Rey, Elisabeth ; Gentet, Jean-Claude ; Chastagner, Pascal ; Vassal, Gilles ; Corradini, Nadège ; Auvrignon, Anne ; Leblond, Pierre ; Rubie, Hervé ; Treluyer, Jean-Marc
  • Peer, Hal (Editor)
  • Assuntos: Etoposide ; Dexamethasone ; Population Pharmacokinetics ; Children ; Anticancer Drugs ; Genetic Polymorphisms ; Medicine ; Pharmacy, Therapeutics, & Pharmacology
  • É parte de: Cancer chemotherapy and pharmacology, 20 May 2010, Vol.67(3), pp.597-603
  • Descrição: Byline: Saik Urien (1,2,13), Francois Doz (2,3), Carole Giraud (1,2), Elisabeth Rey (2,4,5), Jean-Claude Gentet (6), Pascal Chastagner (7), Gilles Vassal (8), Nadege Corradini (9), Anne Auvrignon (10), Pierre Leblond (11), Herve Rubie (12), Jean-Marc Treluyer (1,2,4) Keywords: Etoposide; Dexamethasone; Population pharmacokinetics; Children; Anticancer drugs; Genetic polymorphisms Abstract: Purpose A randomized clinical trial examined whether dexamethasone administration prior to ondansetron followed by etoposide and carboplatin infusions, and single-nucleotide polymorphisms (SNPs) of CYP3A4, CYP3A5 and MDR1 genes could modify etoposide pharmacokinetics in pediatric patients. Methods Patients, 67 children, aged 14 weeks to 16.7 years, were treated for various malignancies and received either 3- or 5-day courses of etoposide and carboplatin: these two drugs were always administered after ondansetron infusion but combined or not with dexamethasone 5 mg/mA2/day 30 min prior to etoposide infusion. Population pharmacokinetics was modeled using a non-linear mixed effect model program (Monolix version 31 s). Results Etoposide pharmacokinetics was ascribed to a 2-compartment model. The most significant covariate effect was bodyweight (BW), so the parameters were standardized to a 70-kg BW using the allometric A3/4 or 1 power model for clearance (CL, Q) or volume terms (V), respectively. The population means for clearance and central volume of distribution were 2.05 l/h/70 kg and 9.21 l/70 kg with the corresponding between-subject variabilities, 0.26 and 0.28. Dexamethasone treatment had no effect on CL, either at the first or at the last administration occasion. CYP3A and MDR1 examined SNPs had no significant effect. Conclusion Pharmacokinetics of etoposide was influenced by BW on an allometric basis in this pediatric population. Dexamethasone did not influence etoposide pharmacokinetics during these 3--5 days courses. These results should allow a better individualization of etoposide dosing in children. Author Affiliation: (1) CIC-0901 Inserm Necker-Cochin and EA-3620, Paris, France (2) Universite Paris Descartes, Paris, France (3) Departement de pediatrie, Institut Curie, Paris, France (4) Pharmacologie, Hopital Cochin-Saint-Vincent-de-Paul, Paris, France (5) Inserm U663, Paris, France (6) Hopital d'Enfants, CHU Timone, Marseille, France (7) Hopital d'Enfants, CHU Nancy, Nancy, France (8) Institut Gustave Roussy, Villejuif, France (9) Hopital Hotel Dieu, Nantes, France (10) Hopital Trousseau, Paris, France (11) Centre Oscar Lambret, Lille, France (12) Unite d'Hemato-Oncologie, Hopital des Enfants, Toulouse, France (13) Unite de Recherche Clinique, Hopital Tarnier, 89 rue d'Assas, 75006, Paris, France Article History: Registration Date: 01/05/2010 Received Date: 11/03/2010 Accepted Date: 30/04/2010 Online Date: 20/05/2010
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.